STADA and Alvotech Secure Approval for Uzpruvo, Europe's
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology,...
Stay updated with breaking news from Oaktree Acquisition. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology,...
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult subjects, met its primary endpoint Alvotech , a global biotech company specializing in...
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European Commission Approvability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food
PrJamteki TM is thesecond biosimilar developedunderthispartnershipthatreceivesmarketingauthorization inCanada.